The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | DRd versus VRd in patients with MM: a real-world retrospective analysis
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses a study comparing time to next treatment (TTNT) in transplant-ineligible patients with multiple myeloma (MM) treated with front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd). The study indicates a significant improvement in TTNT for DRd-treated patients. However, as this is real-world retrospective data, confirmation in a clinical trial setting is necessary. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Takeda, Janssen, Binding Site, Millenium, BMS (Celgene), Sanofi, Regeneron, Pharmacyclics, Pfizer, Merck, Kite, Juno, Bayer, Aztrazeneca, AMGEN, Adaptive Biotechnologies, AbbVie
Membership on Board of Directors/Advisory Committee: AZBio, Antegene, Oncotracker, Caris Life Sciences, Adaptive Biotechnologies
Patents & Royalties: FISH
